HKSE:03320 (Hong Kong)
Â
Registered Shs Unitary 144A/Reg S
HK$
5.91
(+1.55%)
Jun 6
Current and historical daily PE Ratio for China Resources Pharmaceutical Group Ltd (
HKSE:03320
) from 2016 to Jun 06 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. China Resources Pharmaceutical Group stock (HKSE:03320) PE ratio as of Jun 06 2024 is 8.86.
More Details
China Resources Pharmaceutical Group Ltd (HKSE:03320) PE Ratio (TTM) Chart
China Resources Pharmaceutical Group Ltd (HKSE:03320) PE Ratio (TTM) Historical Data
View and export this data going back to 2016. Start your Free Trial
Total 1221
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| China Resources Pharmaceutical Group PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-07 | 8.9 | 2024-04-02 | 7.6 |
| 2024-06-06 | 8.7 | 2024-03-28 | 7.5 |
| 2024-06-05 | 8.7 | 2024-03-27 | 7.6 |
| 2024-06-04 | 8.6 | 2024-03-26 | 7.8 |
| 2024-06-03 | 8.7 | 2024-03-25 | 7.9 |
| 2024-05-31 | 8.7 | 2024-03-22 | 7.7 |
| 2024-05-30 | 8.8 | 2024-03-21 | 7.8 |
| 2024-05-29 | 8.9 | 2024-03-20 | 7.6 |
| 2024-05-28 | 9.1 | 2024-03-19 | 7.5 |
| 2024-05-27 | 9.2 | 2024-03-18 | 7.7 |
| 2024-05-24 | 8.9 | 2024-03-15 | 7.6 |
| 2024-05-23 | 8.9 | 2024-03-14 | 7.7 |
| 2024-05-22 | 9.1 | 2024-03-13 | 7.9 |
| 2024-05-21 | 9.0 | 2024-03-12 | 8.0 |
| 2024-05-20 | 9.3 | 2024-03-11 | 7.8 |
| 2024-05-17 | 9.3 | 2024-03-08 | 7.6 |
| 2024-05-16 | 9.3 | 2024-03-07 | 7.7 |
| 2024-05-14 | 9.3 | 2024-03-06 | 7.8 |
| 2024-05-13 | 9.4 | 2024-03-05 | 7.8 |
| 2024-05-10 | 8.8 | 2024-03-04 | 8.0 |
| 2024-05-09 | 8.4 | 2024-03-01 | 7.9 |
| 2024-05-08 | 7.9 | 2024-02-29 | 8.0 |
| 2024-05-07 | 8.0 | 2024-02-28 | 7.8 |
| 2024-05-06 | 8.0 | 2024-02-27 | 8.0 |
| 2024-05-03 | 7.8 | 2024-02-26 | 7.9 |
| 2024-05-02 | 7.6 | 2024-02-23 | 8.3 |
| 2024-04-30 | 7.6 | 2024-02-22 | 8.2 |
| 2024-04-29 | 7.6 | 2024-02-21 | 8.0 |
| 2024-04-26 | 7.6 | 2024-02-20 | 8.0 |
| 2024-04-25 | 7.4 | 2024-02-19 | 7.7 |
| 2024-04-24 | 7.3 | 2024-02-16 | 7.7 |
| 2024-04-23 | 7.1 | 2024-02-15 | 7.3 |
| 2024-04-22 | 7.3 | 2024-02-14 | 7.3 |
| 2024-04-19 | 7.2 | 2024-02-09 | 7.6 |
| 2024-04-18 | 7.0 | 2024-02-08 | 7.8 |
| 2024-04-17 | 7.1 | 2024-02-07 | 7.6 |
| 2024-04-16 | 7.0 | 2024-02-06 | 7.7 |
| 2024-04-15 | 7.0 | 2024-02-05 | 7.0 |
| 2024-04-12 | 7.1 | 2024-02-02 | 7.2 |
| 2024-04-11 | 7.3 | 2024-02-01 | 7.2 |
| 2024-04-10 | 7.3 | 2024-01-31 | 7.1 |
| 2024-04-09 | 7.3 | 2024-01-30 | 7.3 |
| 2024-04-08 | 7.3 | 2024-01-29 | 7.5 |
| 2024-04-05 | 7.0 | 2024-01-26 | 7.5 |
| 2024-04-03 | 7.6 | 2024-01-25 | 7.6 |
China Resources Pharmaceutical Group Ltd (HKSE:03320) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
China Resources Pharmaceutical Group Ltd
ISIN : HK0000311099
Share Class Description:
HKSE:03320: Registered Shs Unitary 144A/Reg SCompare
Compare
Traded in other countries / regions
03320.Hong Kong640.GermanyCRPGF.USA IPO Date
2016-10-28Description
China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2023, the medical distribution business accounts for 82.6% of its total revenue. CR Pharma's manufacturing business, 17.8% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers